Last reviewed · How we verify

efalizumab plus acitretin

Universita di Verona · FDA-approved active Small molecule

Efalizumab blocks T-cell activation and migration to skin while acitretin reduces keratinocyte proliferation and differentiation, together providing dual immunological and differentiation-based control of psoriasis.

Efalizumab blocks T-cell activation and migration to skin while acitretin reduces keratinocyte proliferation and differentiation, together providing dual immunological and differentiation-based control of psoriasis. Used for Moderate to severe plaque psoriasis.

At a glance

Generic nameefalizumab plus acitretin
SponsorUniversita di Verona
Drug classMonoclonal antibody + retinoid combination
TargetCD11a (LFA-1) + retinoid X receptor (RXR) / retinoid acid receptor (RAR)
ModalitySmall molecule
Therapeutic areaDermatology/Immunology
PhaseFDA-approved

Mechanism of action

Efalizumab is a monoclonal antibody against CD11a that inhibits lymphocyte function-associated antigen-1 (LFA-1), preventing T-cell adhesion and migration to inflamed skin. Acitretin is a retinoid that normalizes keratinocyte differentiation and reduces inflammatory cytokine production. The combination targets both the immune activation and the abnormal skin cell proliferation characteristic of psoriasis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: